QUEBEC CITY, Aug. 16 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ;
NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine therapy
and oncology, today announced the filling of a key position completing the
management team with the appointment of Paul Blake, M.D., as Senior Vice
President and Chief Medical Officer.
"The appointment of Dr. Blake is timely and critical as our foremost
priority is to bring our flagship product candidate, cetrorelix, to market as
a novel treatment in the BPH indication in an expeditious manner", said David
J. Mazzo, Ph.D., President and Chief Executive Officer at AEterna Zentaris.
"Paul brings a wealth of knowledge and is an excellent addition to our team,
with over 25 years of solid experience in clinical development and product
launching for major pharmaceutical companies worldwide. He will be
instrumental in effectively managing our development programs through to
commercialization, specifically our Phase 3 program in BPH for cetrorelix, as
well as focusing on our other high priority drug development programs."
Prior to joining AEterna Zentaris, Dr. Blake was Chief Medical Officer of
Avigenics, Inc. In 2005, he was Senior Vice President, Clinical Research and
Regulatory Affairs at Cephalon, Inc. before being promoted to Executive Vice
President, Worldwide Medical & Regulatory Operations. From 1992 to 1998, he
held the position of Senior Vice President and Medical Director, Clinical
Research and Development at SmithKline Beecham Pharmaceuticals (now GSK).
Dr. Blake earned a medical degree from the London University, Royal Free
Hospital. He was elected Fellow of the American College of Clinical
Pharmacology, Fellow of the Faculty of Pharmaceutical Medicine, Royal College
of Physicians in the UK, and is a Fellow of the Royal College of Physicians in
"Over the recent months, we have made significant progress in
strengthening our core competencies and have undeniably established a world
class team," said Dr. Mazzo. "I believe that with this experienced, highly
competent team along with our rich, self-sustaining pipeline, we have all the
key elements to successfully place AEterna Zentaris in a new growth category
and significantly unlock shareholder value."
Following Dr. Blake's appointment, the Company's Executive Management
Team is comprised of the following members:
- Paul Blake, M.D., Senior Vice President and Chief Medical Officer;
- Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific
- Ellen McDonald, M.B.A., Senior Vice President, Business Operations and
Chief Business Officer;
- Mario Paradis, C.A., Senior Vice President, Administrative and Legal
Affairs, and Corporate Secretary;
- Nicholas J. Pelliccione, Ph.D., Senior Vice President, Regulatory
Affairs and Quality Assurance; and
- Dennis Turpin, C.A., Senior Vice President and Chief Financial Officer.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization.
News releases and additional information are available at
This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Statements that are not historical facts, including statements preceded
by, followed by, or that include the words "believes", "anticipates",
"intends", "plans", "expects", "estimates", "will," "may", "should",
"approximately", and the negative or other variations of those terms or
comparable terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and plans and are
based on certain assumptions.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the ability of AEterna Zentaris to
implement its business strategies, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies,
the ability of AEterna Zentaris to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
For further information:
For further information: Jenene Thomas, Senior Director, Investor
Relations and Corporate Communications, (908) 938-1475,
email@example.com; Media Relations: Paul Burroughs, (418)
652-8525 ext. 406, firstname.lastname@example.org